ISSN 1015 • 3918



ANKARAÜNİVERSİTESİ ECZACILIK **FAKÜLTESİ DERGİSİ**

JOURNAL OF FACULTY OF PHARMACY OF ANKARA UNIVERSITY

Cilt/Vol : 3 1 Sayı /No : 4 Yıl/Year: 2002



ANKARA ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ DERGİSİ

JOURNAL OF FACULTY OF PHARMACY OF ANKARA UNIVERSITY

Cilt/Vol : 31 Sayı/No : 4 Yıl/Year : 2002

Ankara - 2002

ANKARA ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ DERGİSİ (Ankara Ecz, Fak. Derg.)

Sahibi: Prof. Dr. Seçkin ÖZDEN Editör : Prof. Dr. Feyyaz ONUR

Danışma Kurulu:

Asuman KARAKAYA Peter J. HOUGHTON John S. DAVIES Diana ANDERSON Peter Christian SCHMIDT Henry R. BESCH Muzaffer TUNCEL Yusuf ÖZTÜRK Ayşegül DEMİRHAN ERDEMİR İhsan ÇALIŞ Toru OKUYAMA Muhammad Iqbal CHOUDARY Thomas J.SCHMJDT Jack WOOLLEY Henk TIMMERMANN Sevil AŞICI Meral TORUN Esin SENER Maksut COŞKUN Nursin GÖNÜL Nurten ALTANLAR

(Ankara Üniversitesi, Ankara, Türkiye) (Kings College, Londra, İngiltere) (University of Wales, Swansea, İngiltere) (University of Bradford, Bradford, İngiltere) (Eberhard-Karls Universitaet, Tubingen, Almanya) (Indiana University, Indianapolis, USA) (Anadolu Üniversitesi, Eskişehir, Türkiye) (Anadolu Üniversitesi, Eskişehir, Türkiye) (Uludağ Üniversitesi, Bursa, Türkiye) (Hacettepe Üniversitesi, Ankara, Türkiye) (Meiji Pharmaceutical University, Tokyo, Japonya) (University of Karachi, Karachi, Pakistan) (Universitaet Dusseldorf, Dusseldorf, Almanya) (Leiceister University, Leiceister, İngiltere) (Vrije Universiteit, Amsterdam, Hollanda) (Ege Üniversitesi, İzmir, Türkiye) (Gazi Üniversitesi, Ankara, Türkiye) (Ankara Üniversitesi, Ankara, Türkiye) (Ankara Üniversitesi, Ankara, Türkive) (Ankara Üniversitesi, Ankara, Türkiye) (Ankara Üniversitesi, Ankara, Türkiye)

Ankara Üniversitesi Eczacılık Fakültesi Dergisi farmasötik bilimler alanındaki önemli gelişmeleri içeren orijinal araştırmalar, derlemeler ve kısa bildiriler için uluslararası bir yayın ortamıdır. Bu dergi yılda 4 sayı yayınlanır. Yayımlanan yazıların sorumluluğu yazar(lar)ına aittir. Dergiye gönderilen makalelerin daha önce tamamen veya kısmen başka bir yerde yayınlanmamış veya yayını için başka bir yere başvuruda bulunulmamış olması gereklidir. Makaleler derginin arka sayfalarında yer alan yazım kurallarına uymalıdır.

Bu dergi, Chemical Abstracts (CA), Excerpta Medica Database (EMBASE), Medicinal Aromatic Plants Abstracts (MAPA) ve Türk Tıp Dizini 'nde indekslenmektedir.

Web adresi: www.pharmacy.ankara.edu.tr/journal

Yazışma adresi: Prof. Dr. Feyyaz ONUR Ankara Üniversitesi, Eczacılık Fakültesi, Analitik Kimya Anabilim Dalı, 06100 Tandoğan - Ankara, *e-mail:* onur@pharmacy.ankara.edu.tr *Tel:* (0312) 212 68 05, fax: (0312) 213 10 81

Editör Yardımcıları: - Doç. Dr. Gülbin ÖZÇELİKAY - Doç. Dr. İlkay YILDIZ ÖREN *e-mail:* gozcelik@pharmacy.ankara.edu.tr

> Ankara Üniversitesi Basımevi 2002

JOURNAL OF FACULTY OF PHARMACY OF ANKARA UNIVERSITY (J. Fac. Pharm. Ankara)

Published by : Prof. Dr. Seçkin ÖZDEN Editor : Prof. Dr. Feyyaz ONUR

Editorial Board:

Asuman KARAKAYA	(Ankara University, Ankara, Turkey)
Peter J. HOUGHTON	(Kings College, Londra, U.K.)
John S.DAVIES	(University of Wales, Swansea, U.K.)
Diana ANDERSON	(University of Bradford, Bradford, U.K.)
Peter Christian SCHMIDT	(Eberhard-Karls Universitaet, Tubingen, Germany)
Henry R. BESCH	(Indiana University, Indianapolis, USA)
Muzaffer TUNCEL	(Anadolu University, Eskişehir, Turkey)
Yusuf ÖZTÜRK	(Anadolu University, Eskişehir, Turkey)
Ayşegül DEMİRHAN ERDEMİR	(Uludağ University, Bursa, Turkey)
İhsan ÇALIŞ	(Hacettepe University, Ankara, Turkey)
Toru OKUYAMA	(Meiji Pharmaceutical University, Tokyo, Japan)
Muhammad Iqbal CHOUDARY	(University of Karachi, Karachi, Pakistan)
Thomas J.SCHMIDT	(Universitaet Dusseldorf, Dusseldorf, Germany)
Jack WOOLLEY	(Leiceister University, Leiceister, U.K.)
Henk TIMMERMANN	(Vrije Universiteit, Amsterdam, The Netherlands)
Sevil AŞICI	(Ege University, İzmir, Turkey)
Meral TORUN	(Gazi University, Ankara, Turkey)
Esin ŞENER	(Ankara University, Ankara, Turkey)
Maksut COŞKUN	(Ankara University, Ankara, Turkey)
Nurşin GÖNÜL	(Ankara University, Ankara, Turkey)
Nurten ALTANLAR	(Ankara University, Ankara, Turkey)

Journal of Faculty of Pharmacy of Ankara University is an international medium for the publication of original research reports, reviews and short communications on relevant developments in pharmaceutical sciences. This journal is published quarterly. All the articles appeared in this journal are published on the responsibility of the author(s). The manuscript submitted to the journal should not be published previously as a whole or in part and not be submitted elsewhere. The manuscripts should be prepared in accordance with the requirements specified at the end of the issue.

This journal is indexed in Chemical Abstracts (CA), Excerpta Medica Database (EMBASE), Medicinal Aromatic Plants Abstracts (MAPA) and Turkish Medical Index

Web address : www.pharmacy.ankara.edu.tr/journal

Editorial correspondence: Prof. Dr. Feyyaz ONUR Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06100 Tandoğan - Ankara, TURKEY, *e-mail*: onur@pharmacy.ankara.edu.tr *Tel*: +90 312 212 68 05, Fax:+90 312 213 10 81

Editorial assistants: - Assoc. Prof. Dr. Gülbin ÖZÇELİKAY *e-mail:* gozcelik@pharmacy.ankara.edu.tr - Assoc. Prof. Dr. İlkay YILDIZ ÖREN *e-mail:* oren@pharmacy.ankara.edu.tr

> Ankara Üniversitesi Basımevi 2002

İÇİNDEKİLER/CONTENTS

Sayfa

Orjinal Makaleler/Original Articles

Süreyya ÖLGEN, Doğu NEBİOĞLU • Evaluation of indole • 2 • carboxylic acid esters as anti • HIV agents -Indol -2- karboksilik asit esterlerinin anti-HIV ajanlar olarak değerlendirilmesi,	215
Uthman M. DAWOUD, Ali DİŞLİ, Yılmaz YILDIRIR, B. Zühtü UYSAL • Structural elucidation of jojoba plant (Simwondsk Chinmis) oil from Saudia Arabia • Suudi Arabistan'da yetişen Jojoba bitkisi (Simmondsia Chinensis) den elde edilen yağın yapısının aydınlatılması.	223
Filiz KUZ, Gülbin ÖZÇELİKAY • Eczacılık eğitiminde toplam kalite yönetimi uygulanabilirliği II-Ankara'daki Eczacılık Fakültesi öğrencilerinin Fakülte ortamı, Fakülte Şartları ve Üniversite bilinci hakkında değerlendirmeleri • Applicability of total quality management in pharmacy education -II- The evaluation about faculty environment, condition of the faculty and university conciousness by the pharmacy students in Ankara.	231
Valentina PETKOVA, Zlarka DIMITROVA - The assessment of the pharmacy patients compliance in Bulgaria • Bulgaristan'da eczaneye başvuran hastaların uyunç değerlendirmesi.	251
Şebnem Ş. ÇEÇEN, Gülhan CENGİZ, Tülin SÖYLEMEZOĞLU • The protective effects of N- acetylcysteine in paraquat-induced toxicity • Paraquat toksisitesinde N-asetilsisteinin koruyucu etkisi.	259
Derlemeler/Reviews	
Ö. Nazan ERDOĞAN • Sağlık hizmetlerinin bir konusu: Plasebo ve nlasebo etkiler	

• The subject of healthcare services: Placebo and placebo effects. 273

EVALUATION OF INDOLE-2-CARBOXYLIC ACID ESTERS AS ANTI-HIV AGENTS

Süreyya ÖLGEN Doğu NEBİOĞLU

University of Ankara, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06100 Tandoğan, ANKARA-TURKEY

ABSTRACT

The indole esters, which were previously synthesized for inhibition of cyclooxygenase-2 (COX-2), were evaluated for their anti-HIV activities. Among these compounds 4 and 27 were found slightly active against HIV without any cytotoxicity.

Key Words: Indole esters; Anti-HIV activity; Cytotoxicity

ÖZET

Daha önce siklooksigenaz-2 (COX-2) enziminin inhibisyonu için sentezlenen indol esterleri, anti-HIV aktiviteleri için değerlendirilmiştir. Bileşik 4 ve 27, sitotoksisiteleri olmaksızın az da olsa HIV'ye karşı aktif bulunmuşlardır.

Anahtar Kelimeler: İndol esterleri; Anti-HIV aktivitesi; Sitotoksisite

INTRODUCTION

A number of diverse indole derivatives such as; 5-chloro-3-(phenylsulfonyl)indole-2carboxamide (L-737,126) (1), 1-(2-hydroxyethoxy)methylindoles (compounds I) (2) and 5-(2phenyl-3'-indolal)-2-thiohydantoin (compound II) have been shown to have potent anti-HIV activity (human immunodeficiency virus) (3). The structural formula of these compounds are shown in Figure 1. In clinical settings, non-nucleoside class inhibitors of reverse transcriptase (RT) such as nevirapine, have been shown resistant and thus require that this class of inhibitors should be used in combination with other drugs (4). Recent studies were focused on the elimination of the resistance problem against RT mutant. The changing of 2-pyrrolyl substituent to larger rings such as indole on the nevirapine derivatives (compound III) (Figure 1) demonstrated the activity against several clinically relevant forms of HIV-1 reverse transcriptase (5).





Figure 1: Indole-based molecules with anti-HIV activity.

In connection with our research project on indole derivatives, it was noteworthy for evaluating anti-HIV activities of previously synthesized indole esters (6). The formula of tested compounds are shown in Table 1.



Compd.	type of salt	R	R1	R_2
1	HC1	CH_2Ph	Н	methyl
2	HC1	CH_2Ph	Н	ethyl
3	HC1	CH_2Ph	Н	pyrrole
4	HC1	CH_2Ph	Н	pyrimidine
5	HC1	CH_2Ph	CH_3	methyl
6	CH ₃ I	CH ₂ Ph	Н	methyl
7	CH ₃ I	CH ₂ Ph	Н	ethyl
8	CH ₃ I	CH_2Ph	Н	pyrrole
9	CH ₃ I	CH_2Ph	Н	pyrimidine
10	CH ₃ I	CH ₂ Ph	CH ₃	methyl
11	HC1	Ph	Н	methyl
12	HC1	Ph	Н	ethyl
13	HC1	Ph	Н	pyrrole
14	HC1	Ph	Н	pyrimidine
15	HC1	Ph	CH_3	methyl
16	HC1	Ph	Н	piperazine
17	CH ₃ I	Ph	Н	methyl
18	CH ₃ I	Ph	Н	ethyl
19	CH ₃ I	Ph	Н	pyrrole
20	CH ₃ I	Ph	Н	pyrimidine
21	CH ₃ I	Ph	CH_3	methyl
22	HC1	Н	Н	ethyl
23	CH ₃ I	Н	Н	ethyl
24	HC1	Н	Н	pyrrole
25	HC1	Н	Н	pyrimidine
26	HC1	Н	CH ₃	methyl
27	HC1	Н	Н	piperazine

Table 1: Structural formulas of compounds 1-27.

MATERIALS AND METHODS

Candidate compounds were dissolved in dimethylsulfoxide and diluted 1:100 in cell culture medium before preparing serial half-log₁₀ dilutions. T4 lymphocytes (CEM cell line) were added and after a brief interval HIV-1 was added, resulting in a 1:200 final dilution of the compound. Uninfected cells with the compounds served as the toxicity control, and infected and uninfected cells without the compounds served as basic controls. Cultures were incubated at 37°C in a 5% carbon dioxide atmosphere for 6 days. The tetrazolium salt, (XTT) was added to all wells, and cultures were incubated to allow formazon colour development by viable cells. Individual wells were analyzed spectrophotometrically to quantitate formazon production and were viewed by microscopy for detection of viable cells and confirmation of protective activity. Drug-treated virus-infected cells were compared with drug-treated noninfected cells and with other appropriate controls on the same plate. Data were reviewed in comparison with other tests carried on at the same time and the activity was determined.

RESULTS AND DISCUSSION

The procedure used in the National Cancer Institute's test for the agents active against human immunodeficiency virus (HIV) is designed to detect agents acting at any stage of the virus reproductive cycle (7). The assay basically involves the killing of T4 lymphocytes by HIV. Small amounts of HIV are added to cells, and two cycles of virus reproduction are necessary to obtain the required cell killing. Agents that interact with virions, cells or virus gene-products to interfere with viral activities will protect cells from cytolysis. The system is automated in several features to accommodate large numbers of candidate agents and is generally design to detect anti-HIV activity. However, compounds that degenerate or are rapidly metabolized in the culture conditions may not show activity in the screen. All tests are compared with at least one positive AZT-treated control, which was done at the same time under the identical conditions.

The anti-HIV assay of indole esters showed that compounds 4 and 27 were slightly active anti-HIV agents without any cytotoxicity. *In vitro* anti-HIV screening results of compounds 4 and 27 are shown in Figures 2 and 3 and activity against HIV-1 and growth inhibitory properties were placed in Tables 2 and 3 respectively.




Figure 2: In vitro anti-HIV screening of compound 4.




Figure 3: In vitro anti-HIV screening of compound 27.

Table 2: Activity against HIV-1 and growth inhibitory properties of compound 4.

Dose (M)	Percent of protection	Percent of control	
		Infected	Uninfected
6.35 x 10 ⁻⁸	1.31	4.27	90.08
$2.00 \text{ x } 10^{-7}$	-0.54	2.48	89.18
6.34 x 10 ⁻⁷	0.44	3.43	75.08
$2.00 \text{ x } 10^{-6}$	4.95	7.80	88.09
6.33 x 10 ⁻⁶	2.03	4.97	84.32
2.00 x 10 ⁻⁵	-1.25	1.79	69.42
6.32 x 10 ⁻⁵	3.21	6.11	6.06
2.00 x 10 ⁻⁴	-4.06	-0.94	-0.89

Dose (M)	Percent of protection	Percent of control		
		Infected	Uninfected	
6.35 x 10 ⁻⁸	-0.44	2.57	98.71	
2.00 x 10 ⁻⁷	-0.40	2.61	96.41	
6.34 x 10 ⁻⁷	-0.04	2.96	90.31	
2.00 x 10 ⁻⁶	-0.59	2.43	92.43	
6.33 x 10 ⁻⁶	-2.41	0.66	89.87	
2.00 x 10 ⁻⁵	0.92	3.89	72.26	
6.32 x 10 ⁻⁵	1.97	4.91	4.25	
2.00 x 10 ⁻⁴	-4.64	-1.50	-1.33	

Table 3: Activity against HIV-1 and growth inhibitory properties of compound 27.

None of the other derivatives was active and did not exhibit a rather strong cytotoxicity. According to the biological activity result, it can be concluded that N-substitution of indole ring is not important for anti-HIV activity since compound 27 does not have substitution on one position of indole structure. Furthermore, the cyclic groups such as pyrrolidine and piperazine, which constitute the side chain of indole-2-carboxylic acid esters, might have increased the anti-HIV activity of the compounds. Despite these results, the series of compounds presented in this work demonstrated the possibility of modifying indole derivatives that show activity against HIV virus.

ACKNOWLEDGMENTS

This work was supported in part by a grant from the Turkish Scientific and Technical Research Institute (SBAG-AYD-108).

We thank to Dr. V.L. Narayanan (Drug synthesis & Chemistry Branch of National Cancer Institute-U.S.A.) for performing anti-HIV activity tests.

REFERENCES

- Williams, T.M., Ciccarone, T.M., MacTough, S.C., Rooney, C.S., Balani, S.K., Condra, J.H., Emini, E.A., Goldman, M.E., Greenlee, W.J., Kauffman, L.R., O'Brien, J.A., Sardana, V.V., Schleif, W.A., Theoharides, A.D., Anderson, P.S. "5-Chloro 3 (phenylsulfonyl)indole-2-carboxamide: A Novel, Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase", J. Med. Chem. 36, 1291-1294 (1993)
- Almerico, A.M., Barraja, P., Diana, P., Cirrincione, G., Mingoia, F., Musiu, C, Perra, G., Putzolu, M., Marongiu, M.E. "Glycosidopyrroles Part 3. Effect of the benzocondensation on acyclic derivatives: 1-(2-hydroxyethoxy)methylindoles as potential antiviral agents", *IL Farmaco*, 53, 409-414 (1998)
- 3. Suzen, S., Buyukbingol, E. "Evaluation of anti-HIV activity of 5-(2-phenyl-3'-indolyl)-2thiohydantoin", *IL Farmaco*, 53, 525-527 (1998)
- **4.** Murphy, R., Montaner, J. "Nevirapine: a review of its development, pharmacological profile and potential for clinical use", *Exp. Opin. Invest. Drugs*, 5, 1183-1199 (1996)
- Kelly, T.A., McNeil, D.W., Rose, J.M., David, E., Shih, C.-C, Grob, P.M. Novel nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones", J. Med. Chem. 40, 2430-2433 (1997)
- 6. Olgen, S., Akaho, E., Nebioğlu, D. "Synthesis and receptor docking studies of /V-substituted indole-2-carboxylic acid esters as a search for COX-2 selective enzyme inhibitors", *Eur. J. Med. Chem.* 36, 747-770 (2001)
- Weislow, O.W., Kiser, R., Fine, D., Bader, J., Shoemaker, R.H., Boyd, M.R. "New soluble-formazon assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity", *J. Natl. Cancer Inst.* 81, 577-586(1988)

Başvuru Tarihi: 12.07.2002 Kabul Tarihi: 05.08.2002